Novo Nordisk acquires exclusive rights to Hengrui's once-weekly oral GLP-1/GIP agonist HRS-1596 for $300M upfront. Pharma ...

Ortet, a new frontier AI health lab, launches with $500M from Thoreau to build patient-centered foundation models. Learn how ...

AstraZeneca submits NDA to FDA for savolitinib plus osimertinib combination therapy for MET-driven NSCLC. Learn about this ...

Adicet Bio's prula-cel gamma delta CAR-T therapy shows 50% complete renal response in treatment-resistant lupus nephritis ...

Kodiak Sciences' Zenkuda meets primary endpoints in Phase III wAMD trial with 54% of patients reaching 6-month dosing. Learn ...

IASO Bio's RD140 dual-targeted CAR-T therapy shows 88.9% response rate in heavily pretreated myeloma patients. Phase 1 data ...

Alume Biosciences receives FDA Breakthrough Therapy Designation for bevonescein, a fluorescent peptide for nerve ...

Bio secures $48M Series A funding to develop in vivo Th17 cell-targeting therapies for autoimmune diseases. Led by UPMC Enterprises and Ziff Capital.

AstraZeneca invests $2 billion in Summit Therapeutics to accelerate ivonescimab-ADC combination trials. Clinical ...

Arvinas doses first patient in Phase I/II trial of ARV-6723, an oral HPK1 PROTAC degrader for advanced solid tumors.

Sun Pharmaceutical secures exclusive worldwide licensing rights to PCSK9 inhibitor lerodalcibep outside US and China. Read ...

Chugai Pharmaceutical resumes emugrobart development for spinal muscular atrophy after Roche halts obesity trial. Read the latest biotech news.